The global Acute Agitation And Aggression Treatment market is estimated to develop at a compound annual growth rate (CAGR) of 6.4%.
The global Acute Agitation And Aggression Treatment market is estimated to develop at a compound annual growth rate (CAGR) of 6.4%. The global Acute Agitation And Aggression Treatment market size was valued at USD 5.2 billion in 2021, and it is predicted to exceed USD 8.2 billion by 2030. The study investigates several elements and their consequences on the growth of the Acute Agitation And Aggression Treatment market.
Full Report is Ready | Request Sample of This Report @ https://www.novaoneadvisor.com/report/sample/5993
Agitation can be defined as excessive motor or verbal behavior, which can further escalate to aggression. Physical agitation and aggression are manifested in the form of throwing objects toward people, and verbal agitation and aggression manifests as abuses and threats. Acute agitation and aggression are the common symptoms of mental illnesses such as schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression.
Changing attitude toward diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments is the key factor projected to drive the global acute agitation and aggression treatment market during the forecast period.
North America held major share of the global acute agitation and aggression treatment market in 2020. Focus on spreading awareness about treatment related to agitation and aggression among people, increase in economic burden of mental illness, well-established healthcare infrastructure, presence of leading players, and rise in focus of these players on research & development boost the growth of the market in North America.
The acute agitation and aggression treatment market in Asia Pacific is expected to expand at a CAGR of 6.9% from 2022 to 2030. Growth of the market in the region can be attributed to increase in the geriatric population, rise in prevalence of mental illnesses such as schizophrenia & bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.
Report Scope of the Acute Agitation and Aggression Treatment Market
| Report Coverage | Details |
| Market Size | US$ 8.2 Billion by 2030 |
| Growth Rate | CAGR of 6.4% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Increase in Incidence of Dementia in Geriatric Population to Drive Market
Dementia is a condition, which results in decline in memory and other cognitive functions, affecting daily functioning. This condition is more common among the geriatric population. According to the WHO, dementia is expected to affect 82 million people in 2030 and 152 million people in 2050 globally. According to Alzheimer’s Association Report, an estimated 5.8 million people in the U.S. aged 65 and over lived with Alzheimer’s disease in 2020. The number of people aged 65 and older with Alzheimer’s dementia is projected to reach 13.8 million by 2050 owing to increase in the geriatric population. Agitation and aggression are considered the most common symptoms experienced by dementia patients. Therefore, increase in incidence of dementia among the geriatric population is likely to boost the growth of the global acute agitation and aggression treatment during the forecast period.
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/5993
Pharmacologic Approaches (Drugs) Held Major Share of Global Market
In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment dominated the global market in 2020. In emergency care settings, pharmacological approach reduces agitation or aggressive behavior without causing excessive sedation, and ideally avoid invasive administration routes. Traditionally, the following classes of medications have been used to treat agitation: first-generation antipsychotics (FGAs), benzodiazepines (BZDs), and second-generation antipsychotics (SGAs). The growth of the segment can be attributed to the effectiveness of these drugs in controlling agitation and aggression.
Preference for Oral Route for Acute Agitation and Aggression Treatment
Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in 2020, and the trend is anticipated to continue during the forecast period. The growth of the segment can be attributed to the preference for oral medications for the treatment of agitation and aggression
Schizophrenia Dominated Global Market
In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. The schizophrenia segment accounted for major share of the global acute agitation and aggression treatment market in 2020. The segment’s dominance can be attributed to the availability of approved drugs for the treatment of agitation in schizophrenia.
Hospitals & Ambulatory Surgical Centers to be Major End-user
Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for a major share of the global acute agitation and aggression treatment market in 2020. The segment is projected to be driven by increase in mental illness patient visits for emergency treatment.
North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period. Significant investments by the market players in research & development leading to a strong pipeline of drugs for the treatment of agitation in mental illness are the major factors driving the market in North America.
The market in Europe is anticipated to expand at a high CAGR in the near future, owing to significant number of non-government organizations focused on spreading awareness about the treatment for mental illness. For instance, the Alzheimer’s Society in the U.K., a charity organization that creates campaigns to spread awareness about the signs of agitation and aggression in Alzheimer’s, funds research efforts to find a cure for the disease in the region.
The acute agitation and aggression treatment market in Asia Pacific is expected to grow at a rapid pace in the near future. This can be attributed to increase in the geriatric population, rise in prevalence of mental illness such as schizophrenia and bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.
Some of the prominent players in the Acute Agitation And Aggression Treatment market include:
- Eli Lilly and Company
- Pfizer, Inc.
- GlaxoSmithKline
- Otsuka Holdings Co., Ltd.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- Amneal Pharmaceuticals LLC
- H. Lundbeck A/S., among others.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Acute Agitation and Aggression Treatment Market, by Treatment Approach
- Behavioral Approaches
- Environmental Interventions
- Pharmacologic Approaches (Drugs)
- Lorazepam
- Chlorpromazine
- Quetiapine
- Droperidol
- Olanzapine
- Ziprasidone
- Others
Acute Agitation and Aggression Treatment Market, by Indication
- Schizophrenia
- Dementia
- Bipolar Disorder
- Depression
- Drug-induced Agitation & Aggression
- Alcohol Withdrawal
- Others
Acute Agitation and Aggression Treatment Market, by Route of Administration
- Oral
- Intramuscular
- Others
Acute Agitation and Aggression Treatment Market, by End-user
- Hospitals & Ambulatory Surgical Centers
- Psychiatric Care Facilities
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Click Here to View Full Report Table of Contents
Key Questions Answered in Acute Agitation And Aggression Treatment Market Report
What will be the sales/revenue generated by Acute Agitation And Aggression Treatment across all regions during the forecast period?
What are the opportunities in the global Acute Agitation And Aggression Treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which application is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What is the market position of different companies operating in the global market?
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/5993
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth. We for the most part center around supporting our clients with aggressive insight, helping them to anchor an upper hand in the market and achieve reasonable development in various market spaces. Capable with an exceedingly skilled, experienced and to a great degree qualified group of specialists including SMEs, investigators and advisors, we attempt to provide value-added business solutions to our customers. Through dedicated subjective and quantitative market research techniques and supporting consulting assignments, we adeptly formulate competitive strategies to address business challenges for our customers through investigating market drifts, trends and rising advances in emerging technologies.
For Latest Update Follow Us:
https://www.linkedin.com/company/nova-one-advisor
https://twitter.com/NovaOneAdvisor
https://www.facebook.com/Nova-One-Advisor-116142276949837/